Plank David M, Yatani Atsuko, Ritsu Honda, Witt Sandra, Glascock Betty, Lalli M Jane, Periasamy Muthu, Fiset Celine, Benkusky Nancy, Valdivia Hector H, Sussman Mark A
Divisions of Molecular Cardiovascular Biology, The Children's Hospital and Research Foundation, Cincinnati, OH 45229, USA.
Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H305-15. doi: 10.1152/ajpheart.00425.2002. Epub 2003 Mar 20.
Changes in calcium (Ca2+) regulation contribute to loss of contractile function in dilated cardiomyopathy. Clinical treatment using beta-adrenergic receptor antagonists (beta-blockers) slows deterioration of cardiac function in end-stage heart failure patients; however, the effects of beta-blocker treatment on Ca2+ dynamics in the failing heart are unknown. To address this issue, tropomodulin-overexpressing transgenic (TOT) mice, which suffer from dilated cardiomyopathy, were treated with a nonselective beta-receptor blocker (5 mg. kg-1. day-1 propranolol) for 2 wk. Ca2+ dynamics in isolated cardiomyocytes of TOT mice significantly improved after treatment compared with untreated TOT mice. Frequency-dependent diastolic and Ca2+ transient amplitudes were returned to normal in propranolol-treated TOT mice and but not in untreated TOT mice. Ca2+ kinetic measurements of time to peak and time decay of the caffeine-induced Ca2+ transient to 50% relaxation were also normalized. Immunoblot analysis of untreated TOT heart samples showed a 3.6-fold reduction of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), whereas Na+/Ca2+ exchanger (NCX) concentrations were increased 2.6-fold relative to nontransgenic samples. Propranolol treatment of TOT mice reversed the alterations in SERCA and NCX protein levels but not potassium channels. Although restoration of Ca2+ dynamics occurred within 2 wk of beta-blockade treatment, evidence of functional improvement in cardiac contractility assessed by echocardiography took 10 wk to materialize. These results demonstrate that beta-adrenergic blockade restores Ca2+ dynamics and normalizes expression of Ca2+-handling proteins, eventually leading to improved hemodynamic function in cardiomyopathic hearts.
钙(Ca2+)调节的变化导致扩张型心肌病收缩功能丧失。使用β-肾上腺素能受体拮抗剂(β受体阻滞剂)的临床治疗可减缓终末期心力衰竭患者心脏功能的恶化;然而,β受体阻滞剂治疗对衰竭心脏中Ca2+动力学的影响尚不清楚。为了解决这个问题,对患有扩张型心肌病的过表达原肌球蛋白转基因(TOT)小鼠用非选择性β受体阻滞剂(5 mg·kg-1·天-1普萘洛尔)治疗2周。与未治疗的TOT小鼠相比,治疗后TOT小鼠分离心肌细胞中的Ca2+动力学显著改善。在普萘洛尔治疗的TOT小鼠中,频率依赖性舒张期和Ca2+瞬变幅度恢复正常,而未治疗的TOT小鼠则未恢复。咖啡因诱导的Ca2+瞬变至50%松弛的峰值时间和衰减时间的Ca2+动力学测量也恢复正常。未治疗的TOT心脏样本的免疫印迹分析显示,肌浆网Ca2+-ATP酶(SERCA)减少了3.6倍,而钠/钙交换体(NCX)浓度相对于非转基因样本增加了2.6倍。普萘洛尔治疗TOT小鼠可逆转SERCA和NCX蛋白水平的改变,但对钾通道无影响。虽然在β受体阻滞剂治疗的2周内Ca2+动力学恢复,但通过超声心动图评估的心脏收缩功能改善的证据需要10周才能显现。这些结果表明,β-肾上腺素能阻断可恢复Ca2+动力学并使Ca2+处理蛋白的表达正常化,最终改善心肌病心脏的血流动力学功能。